Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: Sam Lee who wrote (95)	6/4/1998 1:11:00 PM
From: Robert Floyd	Read Replies (1) \| Respond to of 320

I have doubled my investment over the past couple of months. I think great things are going to happen to this stock before the year is out. My prediction is over 7 by year's end.

To: Sam Lee who wrote (95)	6/15/1998 5:17:00 PM
From: Robert Floyd	Read Replies (1) \| Respond to of 320

NEW YORK, BIO'98 Investor & Partnering Conference, June 15 /PRNewswire/ -- Geoffrey F. Cox, Ph.D., Chairman and CEO of Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX - news) presented to investors at the BIO'98 Investor & Partnering Conference on Monday, June 15, 1998. Aronex Pharmaceuticals, Inc. is a Texas-based biopharmaceutical company that develops and commercializes proprietary innovative medicines to treat cancer and infectious diseases. The Company has five products in clinical development, two of which are approaching commercialization, as well as a pipeline of additional products. The Company is poised to enter into commercialization with a particularly strong management team of experienced pharmaceutical executives, who collectively have many decades of experience in the development and marketing of pharmaceuticals. Their backgrounds include successful companies such as Genzyme Corporation [Nasdaq:GENZ - news], Johnson & Johnson, Sandoz, Agouron, Genentech, Schering- Plough, Bristol-Myers Squibb, Marion Merrill Dow and Glaxo. Aronex Pharmaceuticals' two lead products, ATRAGEN(R) and NYOTRAN(TM) have demonstrated advantages over existing therapies and are expected to address large and under-served markets. NYOTRAN, a liposomal formulation of nystatin for use against systemic fungal infections, is in pivotal Phase III multi- center trials in the U.S. and Europe. NYOTRAN has demonstrated differentiating antifungal activity in over 500 samples in multiple in vitro studies against a variety of fungal species, including Aspergillus and Candida. There are close to 300,000 systemic fungal infections worldwide each year and the annual market for anti-fungal drugs is growing. ATRAGEN, in pivotal Phase II trials, is a liposomal formulation of all- trans retinoic acid (ATRA) for use in inducing remission and preventing relapse in cancer patients. Clinical studies have demonstrated that ATRAGEN achieves higher and more sustained blood levels, and has a reduced toxicity profile than existing therapies. Aronex Pharmaceuticals plans to file a New Drug Application for acute promyelocytic leukemia (APL) and initiate Phase III clinical trials for acute myelocytic leukemia (AML) this year. The company is reviewing other pilot studies to examine the efficacy of ATRAGEN in non- Hodgkin's lymphoma, prostate cancer, renal cell cancer, head and neck cancer and bladder cancer. Collectively, these indications account for approximately 350,000 annual incidences worldwide. Other products in Aronex Pharmaceuticals' portfolio include: Annamycin, Zintevir(TM) and Platar (AR726). Annamycin, in Phase II trials in refractory breast cancer, is a novel liposomal anthracycline designed to overcome severe cardiotoxicity and multiple drug resistance. Zintevir is an HIV integrase inhibitor that is currently being evaluated in a Phase I/II clinical trial to test the safety, anti-viral activity and pharmacokinetics in HIV patients. Platar (AR726) is a liposomal platinum prodrug for solid tumor treatments. Initial clinical development of AR726 in cancer patients with mesothelioma has been conducted under an institutional IND at M.D. Anderson Cancer Center, Aronex Pharmaceuticals'collaborator. SOURCE: Aronex Pharmaceuticals, Inc. --------------------------------------------------------------------------------